Concordia International Corp. (NASDAQ: CXRX) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitabiliy, dividends, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Concordia International Corp. and Taro Pharmaceutical Industries’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Concordia International Corp. -185.54% -83.96% 0.78%
Taro Pharmaceutical Industries 49.69% 20.08% 18.00%

Earnings & Valuation

This table compares Concordia International Corp. and Taro Pharmaceutical Industries’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Concordia International Corp. $748.18 million 0.09 $380.70 million ($27.05) -0.05
Taro Pharmaceutical Industries $806.92 million 4.88 $465.05 million $9.82 9.90

Taro Pharmaceutical Industries has higher revenue and earnings than Concordia International Corp.. Concordia International Corp. is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Concordia International Corp. and Taro Pharmaceutical Industries, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Concordia International Corp. 6 2 0 0 1.25
Taro Pharmaceutical Industries 0 1 0 0 2.00

Concordia International Corp. presently has a consensus target price of $9.80, indicating a potential upside of 653.85%. Given Concordia International Corp.’s higher possible upside, research analysts clearly believe Concordia International Corp. is more favorable than Taro Pharmaceutical Industries.

Risk & Volatility

Concordia International Corp. has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.

Institutional & Insider Ownership

13.7% of Concordia International Corp. shares are held by institutional investors. Comparatively, 16.4% of Taro Pharmaceutical Industries shares are held by institutional investors. 13.8% of Taro Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Taro Pharmaceutical Industries beats Concordia International Corp. on 12 of the 13 factors compared between the two stocks.

About Concordia International Corp.

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company’s owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company’s other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.

Receive News & Ratings for Concordia International Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia International Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.